文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

miR-9和miR-223在复发性卵巢癌中的潜在作用。

Potential role of miR-9 and miR-223 in recurrent ovarian cancer.

作者信息

Laios Alexandros, O'Toole Sharon, Flavin Richard, Martin Cara, Kelly Lynn, Ring Martina, Finn Stephen P, Barrett Ciara, Loda Massimo, Gleeson Noreen, D'Arcy Tom, McGuinness Eamonn, Sheils Orla, Sheppard Brian, O' Leary John

机构信息

Department of Obstetrics and Gynaecology, Trinity College Dublin, Trinity Centre for Health Sciences, St, James's Hospital, Dublin 8, Ireland.

出版信息

Mol Cancer. 2008 Apr 28;7:35. doi: 10.1186/1476-4598-7-35.

DOI:10.1186/1476-4598-7-35
PMID:18442408
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2383925/
Abstract

BACKGROUND: MicroRNAs (miRNAs) are small, noncoding RNAs that negatively regulate gene expression by binding to target mRNAs. miRNAs have not been comprehensively studied in recurrent ovarian cancer, yet an incurable disease. RESULTS: Using real-time RT-PCR, we obtained distinct miRNA expression profiles between primary and recurrent serous papillary ovarian adenocarcinomas (n = 6) in a subset of samples previously used in a transcriptome approach. Expression levels of top dysregulated miRNA genes, miR-223 and miR-9, were examined using TaqMan PCR in independent cohorts of fresh frozen (n = 18) and FFPE serous ovarian tumours (n = 22). Concordance was observed on TaqMan analysis for miR-223 and miR-9 between the training cohort and the independent test cohorts. Target prediction analysis for the above miRNA "recurrent metastatic signature" identified genes previously validated in our transcriptome study. Common biological pathways well characterised in ovarian cancer were shared by miR-9 and miR-223 lists of predicted target genes. We provide strong evidence that miR-9 acts as a putative tumour suppressor gene in recurrent ovarian cancer. Components of the miRNA processing machinery, such as Dicer and Drosha are not responsible for miRNA deregulation in recurrent ovarian cancer, as deluded by TaqMan and immunohistochemistry. CONCLUSION: We propose a miRNA model for the molecular pathogenesis of recurrent ovarian cancer. Some of the differentially deregulated miRNAs identified correlate with our previous transcriptome findings. Based on integrated transcriptome and miRNA analysis, miR-9 and miR-223 can be of potential importance as biomarkers in recurrent ovarian cancer.

摘要

背景：微小RNA（miRNA）是一类小的非编码RNA，通过与靶mRNA结合来负向调节基因表达。miRNA在复发性卵巢癌（一种无法治愈的疾病）中尚未得到全面研究。 结果：使用实时逆转录聚合酶链反应（RT-PCR），我们在先前用于转录组分析的一部分样本中，获得了原发性和复发性浆液性乳头状卵巢腺癌（n = 6）之间不同的miRNA表达谱。使用TaqMan PCR在独立的新鲜冷冻（n = 18）和福尔马林固定石蜡包埋（FFPE）浆液性卵巢肿瘤队列（n = 22）中检测了上调最明显的miRNA基因miR-223和miR-9的表达水平。在训练队列和独立测试队列之间，TaqMan分析观察到miR-223和miR-9的一致性。对上述miRNA“复发转移特征”的靶标预测分析确定了先前在我们的转录组研究中得到验证的基因。miR-9和miR-223预测靶基因列表共享了在卵巢癌中特征明确的常见生物学途径。我们提供了强有力的证据表明，miR-9在复发性卵巢癌中作为一种假定的肿瘤抑制基因发挥作用。正如TaqMan和免疫组织化学所证实的，miRNA加工机制的组成部分，如Dicer和Drosha，与复发性卵巢癌中miRNA的失调无关。 结论：我们提出了一个关于复发性卵巢癌分子发病机制的miRNA模型。一些鉴定出的差异失调miRNA与我们之前的转录组研究结果相关。基于整合的转录组和miRNA分析，miR-9和miR-223作为复发性卵巢癌的生物标志物可能具有潜在重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de71/2383925/d32dcbe57c67/1476-4598-7-35-9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de71/2383925/0cfd7888e95d/1476-4598-7-35-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de71/2383925/9a377731dee9/1476-4598-7-35-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de71/2383925/05a671ab38cf/1476-4598-7-35-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de71/2383925/9cdaef871b00/1476-4598-7-35-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de71/2383925/5c76b03d89dc/1476-4598-7-35-5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de71/2383925/5ec8b89e3732/1476-4598-7-35-6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de71/2383925/9934db6a4e55/1476-4598-7-35-7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de71/2383925/78d68925ebf4/1476-4598-7-35-8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de71/2383925/d32dcbe57c67/1476-4598-7-35-9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de71/2383925/0cfd7888e95d/1476-4598-7-35-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de71/2383925/9a377731dee9/1476-4598-7-35-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de71/2383925/05a671ab38cf/1476-4598-7-35-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de71/2383925/9cdaef871b00/1476-4598-7-35-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de71/2383925/5c76b03d89dc/1476-4598-7-35-5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de71/2383925/5ec8b89e3732/1476-4598-7-35-6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de71/2383925/9934db6a4e55/1476-4598-7-35-7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de71/2383925/78d68925ebf4/1476-4598-7-35-8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de71/2383925/d32dcbe57c67/1476-4598-7-35-9.jpg

相似文献

[1]
Potential role of miR-9 and miR-223 in recurrent ovarian cancer.

Mol Cancer. 2008-4-28

[2]
miRNA profiling along tumour progression in ovarian carcinoma.

J Cell Mol Med. 2011-7

[3]
Overexpression of microRNA-196b Accelerates Invasiveness of Cancer Cells in Recurrent Epithelial Ovarian Cancer Through Regulation of Homeobox A9.

Cancer Genomics Proteomics. 2017

[4]
Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma.

Hum Pathol. 2012-5-29

[5]
Novel miRNA genes deregulated by aberrant methylation in ovarian carcinoma are involved in metastasis.

Gene. 2018-4-6

[6]
Dicer, Drosha, and outcomes in patients with ovarian cancer.

N Engl J Med. 2008-12-18

[7]
Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.

PLoS One. 2015-10-20

[8]
Primary and recurrent ovarian high-grade serous carcinomas display similar microRNA expression patterns relative to those of normal ovarian tissue.

Oncotarget. 2016-10-25

[9]
miR-223 potentially targets SWI/SNF complex protein SMARCD1 in atypical proliferative serous tumor and high-grade ovarian serous carcinoma.

Hum Pathol. 2017-10-24

[10]
Transcription factor-microRNA-target gene networks associated with ovarian cancer survival and recurrence.

PLoS One. 2013-3-12

引用本文的文献

[1]
Long Non-Coding RNA LINC01116 Promotes the Proliferation of Lung Adenocarcinoma by Targeting miR-9-5p/CCNE1 Axis.

J Cell Mol Med. 2024-12

[2]
Unraveling the extracellular vesicle network: insights into ovarian cancer metastasis and chemoresistance.

Mol Cancer. 2024-9-16

[3]
Non-coding RNAs as therapeutic targets in cancer and its clinical application.

J Pharm Anal. 2024-7

[4]
MiR-223-3p in Cancer Development and Cancer Drug Resistance: Same Coin, Different Faces.

Int J Mol Sci. 2024-7-26

[5]
Diagnostic value of plasma-derived exosomal miR-223 for epithelial ovarian cancer.

BMC Womens Health. 2024-3-2

[6]
A diagnostic miRNA panel to detect recurrence of ovarian cancer through artificial intelligence approaches.

J Cancer Res Clin Oncol. 2023-1

[7]
Deregulated miRNA clusters in ovarian cancer: Imperative implications in personalized medicine.

Genes Dis. 2022-3-1

[8]
The potential applications of microparticles in the diagnosis, treatment, and prognosis of lung cancer.

J Transl Med. 2022-9-5

[9]
Initiation and elongation factor co-expression correlates with recurrence and survival in epithelial ovarian cancer.

J Ovarian Res. 2022-6-19

[10]
Relevance of miR-223 as Potential Diagnostic and Prognostic Markers in Cancer.

Biology (Basel). 2022-2-6

本文引用的文献

[1]
Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma.

Cancer Genet Cytogenet. 2008-2

[2]
An integrative model for recurrence in ovarian cancer.

Mol Cancer. 2008-1-22

[3]
MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN.

Cancer Res. 2008-1-15

[4]
Argonaute proteins: key players in RNA silencing.

Nat Rev Mol Cell Biol. 2008-1

[5]
Targeting microRNA expression to regulate angiogenesis.

Trends Pharmacol Sci. 2008-1

[6]
Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells.

Nat Cell Biol. 2007-12

[7]
Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer.

J Pathol. 2008-1

[8]
Laser capture microdissection technology.

Expert Rev Mol Diagn. 2007-9

[9]
MicroRNA signatures in human ovarian cancer.

Cancer Res. 2007-9-15

[10]
Differential expression of microRNAs with progression of gestation and inflammation in the human chorioamniotic membranes.

Am J Obstet Gynecol. 2007-9

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索